Verapamil and Norverapamil Plasma Concentrations During Long‐Term Therapy in Patients with Hypertrophic Obstructive Cardiomyopathy

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  1980-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00005344-198001000-00003PMID 6154201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gas chromatographic determination of verapamil in plasma and urine.

  1979cited by this paper
• Treatment of hypertrophic obstructive cardiomyopathy with verapamil.

  1979cited by this paper
• Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

  1978cited by this paper
• Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

  1977cited by this paper
• Protein Binding and Kinetics of Drugs in Liver Diseases

  1977cited by this paper
• [Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].

  1976cited by this paper
• Physiological disposition of verapamil in man.

  1976cited by this paper
• Metabolism of [14C]verapamil.

  1971cited by this paper

• Metabolite Parameters as an Appropriate Alternative Approach for Assessment of Bioequivalence of Two Verapamil Formulations

  2014cites this paper
• Pharmacokinetics of diltiazem and other calcium entry blockers.

  2009cites this paper
• Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.

  2009cites this paper
• VERAPAMIL BIOAVAILABILITY AND DOSAGE IN LIVER DISEASE

  2006cites this paper
• Quin 2 Microfluorometry and Effects of Verapamil and Diltiazem on Calcium Release From Rat Aorta Smooth Muscle Cells in Primary Culture

  2005cites this paper
• Verapamiland Calcium-StimulatedEnzyme Effluxfrom Skeletal Muscle

  2004cites this paper
• Gas-ChromatographicDeterminationof Verapamiland Norverapamil , with a Nitrogen-SelectiveDetector

  2004cites this paper
• Clinical pharmacokinetics of verapamil in patients with atrial fibrillation

  2004cites this paper
• Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection.

  1997cites this paper
• Verapamil and Norverapamil Plasma Levels in Infants and Children During Chronic Oral Treatment

  1995cites this paper
• Effect of acute smoking on red blood cell deformability in healthy young and elderly non-smokers, and effect of verapamil on age- and acute smoking-induced change in red blood cell deformability.

  1994cites this paper
• Pharmacokinetics of the enantiomers of verapamil in the dog.

  1993cites this paper
• Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia

  1993cites this paper
• Measurement of plasma verapamil levels by high-performance liquid chromatography.

  1993cites this paper
• Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia.

  1993cites this paper
• Relaxation effects of diltiazem, verapamil, and tolazoline on isolated cat ophthalmociliary artery.

  1992cites this paper
• Comparative bioavailability of verapamil from rapidly absorbed and slow release preparations.

  1992cites this paper
• Influence of time of administration on verapamil pharmacokinetics

  1992cites this paper
• Metabolites of Antihypertensive Drugs

  1991cites this paper
• Double-blind randomised placebo-controlled dose-efficacy study of sustained release verapamil in chronic stable angina.

  1991cites this paper
• Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

  1991cites this paper
• Requirements for drug monitoring of verapamil: experience from an unselected group of patients with cardiovascular disease.

  1990cites this paper
• Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.

  1990cites this paper
• Relationships between verapamil plasma concentrations and its antihypertensive action.

  1988cites this paper
• Quin2 microfluorometry and effects of verapamil and diltiazem on calcium release from rat aorta smooth muscle cells in primary culture.

  1988cites this paper
• Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.

  1988cites this paper
• Clinical pharmacology of verapamil.

  1988cites this paper
• Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.

  1988cites this paper
• Effects of verapamil and diltiazem on human platelet function.

  1987cites this paper
• Clinical and biochemical effects of verapamil administration to schizophrenic patients.

  1987cites this paper
• Fatal verapamil poisoning.

  1987cites this paper
• Cardiovascular drugs. I: Antidysrhythmic drugs.

  1986cites this paper
• Characteristics of the inhibition of ligand binding to serotonin receptors in rat brain membranes by verapamil.

  1986cites this paper
• Twice-daily administration of oral verapamil in the treatment of essential hypertension.

  1986cites this paper
• [Dynamics of the anti-anginal effect and of the concentrations of verapamil and its metabolites in the blood serum of patients with stenocardia of exertion].

  1986cites this paper
• Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem

  1986cites this paper
• Effects of verapamil on pharmacokinetics and pharmacodynamics of digitoxin in patients.

  1985cites this paper
• Verapamil-Rifampin Interaction

  1985cites this paper
• Hemodynamic effects of verapamil in left ventricular valvular volume overload.

  1985cites this paper
• Rapid gas-liquid chromatographic method for plasma verapamil level determination.

  1985cites this paper
• Effects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis.

  1985cites this paper
• [Pharmacodynamic comparison of propranolol and verapamil in exertion stenocardia].

  1984cites this paper
• Clinical Pharmacokinetics of Verapamil

  1984cites this paper
• [Verapamil: antiangina effects].

  1984cites this paper
• Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure.

  1984cites this paper
• Calcium antagonists and endocrine status: lack of effect of oral verapamil on pituitary-testicular and pituitary-thyroid function.

  1984cites this paper
• Pharmakokinetische Prinzipien und spezielle Pharmakokinetik der Antiarrhythmika

  1983cites this paper
• Relaxation of Large Coronary Artery by Verapamil, D600, and Nifedipine is Constrictor Selective: Comparison with Glyceryl Trinitrate

  1983cites this paper
• Clinical use of antiarrhythmic drugs

  1983cites this paper
• Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure

  1983cites this paper
• Aspects of the clinical pharmacology of verapamil, a calcium‐entry antagonist

  1983cites this paper
• Cellular membranes in Duchenne muscular dystrophy.

  1983cites this paper
• Verapamil in atrial fibrillation: The expected, the unexpected, and the unknown.

  1983cites this paper
• PQ-intervals and serum concentrations as indices of verapamil absorption following sublingual, buccal and per oral administration in man.

  1983cites this paper
• Responses of dog large coronary arteries to constrictor and dilator substances: implications for the cause and treatment of variant angina pectoris.

  1983cites this paper
• The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

  1983cites this paper
• Calcium antagonists: a new class of drugs.

  1983cites this paper
• Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study.

  1983cites this paper
• Verapamil bioavailability and dosage in liver disease.

  1982cites this paper
• Acute and Chronic Pharmacodynamic Interaction of Verapamil and Digoxin in Atrial Fibrillation

  1982cites this paper
• Interaction of verapamil with human platelet alpha-adrenergic receptors.

  1982cites this paper
• Atopy predisposing to acute bronchiolitis during an epidemic of respiratory syncytial virus.

  1982cites this paper
• [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].

  1982cites this paper
• Verapamil: a selective antagonist of constrictor substances in dog coronary artery: implications for variant angina.

  1982cites this paper
• Verapamil and calcium-stimulated enzyme efflux from skeletal muscle.

  1982cites this paper
• Verapamil Hydrochloride: Pharmacological Properties and Role in Cardiovascular Therapeutics

  1982cites this paper
• Additive antianginal effect of verapamil in patients receiving propranolol

  1982cites this paper
• Electropharmacology of the Slow‐Channel Inhihitors in the Management of Cardiac Arrhythmias: Verapamil

  1982cites this paper
• [Conservative medical treatment of hypertrophic myocardiopathies].

  1982cites this paper
• The Effects of Intravenous Verapamil on Hemodynamic Status of Patients with Coronary Artery Disease Receiving Propranolol

  1982cites this paper
• [Drugs with first-pass elimination. Verapamil and dihydroergotamine alkaloids].

  1982cites this paper
• Clinical pharmacology of slow channel blocking agents.

  1982cites this paper
• Gas-chromatographic determination of verapamil and norverapamil, with a nitrogen-selective detector.

  1982cites this paper
• Metabolism of the perfused rabbit heart. V. Verapamil-induced release of creatine kinase.

  1982cites this paper
• Clinical relevance of verapamil plasma levels in stable angina pectoris.

  1982cites this paper
• Correlation of Verapamil Plasma Levels with Electrocardiographic and Hemodynamic Effects

  1982cites this paper
• Plasma Verapamil Levels in Patients with Hypertrophic Cardiomyopathy: Interpatient Variability and Clinical Usefulness

  1982cites this paper
• Verapamil Plasma Concentrations and Indices of Heart Size in Hypertrophic Obstructive Cardiomyopathy - Evidence for the Existence of a Therapeutic Range

  1982cites this paper
• The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses

  1982cites this paper
• Direct determination of hepatic extraction of verapamil in cardiac patients

  1981cites this paper
• The Pharmacology of Verapamil. III. Pharmacokinetics in Normal Subjects After Intravenous Drug Administration

  1981cites this paper
• Pharmacokinetics of verapamil

  1981cites this paper
• Successful treatment of suicidal verapamil poisoning with calcium gluconate.

  1981cites this paper
• Verapamil disposition in liver disease and intensive‐care patients: Kinetics, clearance, and apparent blood flow relationships

  1981cites this paper
• New Antiarrhythmic Drugs: Their Place in Therapy

  1981cites this paper
• Evaluation of the clinical significance of the first-pass effect of verapamil in patients

  1980cites this paper
• Comparative pharmacokinetics of new antiarrhythmic drugs.

  1980cites this paper
• Measurement of verapamil concentrations in plasma by gas chromatography and high pressure liquid chromatography.

  1980cites this paper